Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Enanta Pharmaceuticals, Inc is a biotechnology business based in the US. Enanta Pharmaceuticals shares (ENTA) are listed on the NASDAQ and all prices are listed in US Dollars. Enanta Pharmaceuticals employs 132 staff and has a trailing 12-month revenue of around USD$150.2 million.
Since the stock market crash in March caused by coronavirus, Enanta Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$45.34, which is 14.77% down on its pre-crash value of USD$53.2 and 18.07% up on the lowest point reached during the March crash when the shares fell as low as USD$38.4.
If you had bought USD$1,000 worth of Enanta Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$869.91 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$858.74.
|Latest market close||USD$45.34|
|52-week range||USD$38.4 - USD$65.755|
|50-day moving average||USD$46.4056|
|200-day moving average||USD$49.7218|
|Wall St. target price||USD$67.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.119|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||2.60%|
|1 month (2020-10-23)||3.40%|
|3 months (2020-08-25)||-10.47%|
|6 months (2020-05-22)||-18.01%|
|1 year (2019-11-25)||-27.68%|
|2 years (2018-11-23)||-42.60%|
|3 years (2017-11-24)||-5.27%|
|5 years (2015-11-25)||41.69%|
Valuing Enanta Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enanta Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Enanta Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 447x. In other words, Enanta Pharmaceuticals shares trade at around 447x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Enanta Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$14.8 million.
The EBITDA is a measure of a Enanta Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$150.2 million|
|Gross profit TTM||USD$205.2 million|
|Return on assets TTM||-1.96%|
|Return on equity TTM||0.51%|
|Market capitalisation||USD$873.3 million|
TTM: trailing 12 months
There are currently 2.1 million Enanta Pharmaceuticals shares held short by investors – that's known as Enanta Pharmaceuticals's "short interest". This figure is 2.8% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Enanta Pharmaceuticals shares can be evaluated.
Enanta Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Enanta Pharmaceuticals shares currently shorted divided by the average quantity of Enanta Pharmaceuticals shares traded daily (recently around 194417.74042951). Enanta Pharmaceuticals's SIR currently stands at 10.71. In other words for every 100,000 Enanta Pharmaceuticals shares traded daily on the market, roughly 10710 shares are currently held short.
However Enanta Pharmaceuticals's short interest can also be evaluated against the total number of Enanta Pharmaceuticals shares, or, against the total number of tradable Enanta Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enanta Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Enanta Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1269% of the tradable shares (for every 100,000 tradable Enanta Pharmaceuticals shares, roughly 127 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Enanta Pharmaceuticals.
Find out more about how you can short Enanta Pharmaceuticals stock.
We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Enanta Pharmaceuticals's shares have ranged in value from as little as $38.4 up to $65.755. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.4231. This would suggest that Enanta Pharmaceuticals's shares are less volatile than average (for this exchange).
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.